Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
10.1242/jcs.00420 76 WeiX.WangS.ZhengW
Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2 Antagonist in patients with previously treated advanced clear cell renal cell carcinoma
GHK-Cu does not directly interact with cytoskeletal proteins but instead operates through copper-dependent enzymatic activation and transcriptomic reprogramming
The infusion includes B-vitamins, glutathione, and MIC
33 PetersonB
Future studies utilizing high-resolution temporal profiling of m 6 A modifications could provide additional insights into the regulatory mechanisms controlling cell fate transitions
US$ 29.41
US$ 27.93
US$ 22.36
US$ 20.14
